International Stem Cell (ISCO) Equity Ratio (2016 - 2025)
International Stem Cell (ISCO) has disclosed Equity Ratio for 16 consecutive years, with 0.71 as the latest value for Q3 2025.
- On a quarterly basis, Equity Ratio rose 8.36% to 0.71 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.71, a 8.36% increase, with the full-year FY2024 number at 0.76, up 2.2% from a year prior.
- Equity Ratio was 0.71 for Q3 2025 at International Stem Cell, down from 0.7 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.66 in Q2 2023 to a low of 0.93 in Q4 2021.
- A 5-year average of 0.79 and a median of 0.78 in 2024 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: tumbled 88.78% in 2021, then rose 25.86% in 2023.
- International Stem Cell's Equity Ratio stood at 0.93 in 2021, then grew by 5.11% to 0.88 in 2022, then rose by 11.75% to 0.78 in 2023, then rose by 2.2% to 0.76 in 2024, then grew by 5.9% to 0.71 in 2025.
- Per Business Quant, the three most recent readings for ISCO's Equity Ratio are 0.71 (Q3 2025), 0.7 (Q2 2025), and 0.73 (Q1 2025).